| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27e1ea5f65e8f958e48f1a9d53fdbb45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2410-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4cbbbae17e3fd44b16ba25a93c30660 |
| publicationDate |
2019-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019234952-A1 |
| titleOfInvention |
Methods of detecting hypoxia-associate peptides |
| abstract |
In certain embodiments, the present invention provides a method of detecting hypoxia status in a tumor cell by detecting a level of hydroxyprolyl BK (Hyp-BK) peptides in a patient sample, and detecting a level of bradykinin (BK) peptides the patient sample, wherein a change in the Hyp-BK/BK ratio as compared to the Hyp-BK/BK ratio in a comparable normal cell is a marker for tumor hypoxia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11085929-B2 |
| priorityDate |
2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |